- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 2,816
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
- Interventions
- Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
- Drug · Radiation · Procedure
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
- Conditions
- ALL, Adult, CNS Tumor, Solid Tumor
- Interventions
- Neurocognitive (Thinking) Testing, CNS Vital Signs (Thinking) Testing, Health Questionnaires, Sleep Surveys & Sleep Diary, Echocardiography/EKG, Pulmonary Function, Remote Polysomnography, Physical Function
- Other · Diagnostic Test · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Interventions
- Not listed
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 10
- States / cities
- Brisbane, California • Duarte, California • Tampa, Florida + 7 more
- Conditions
- Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Interventions
- CC-486 (5-azacitidine), Duvelisib, Romidepsin, Doxorubicin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
- Interventions
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
- Biological
- Lead sponsor
- Guenther Koehne
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- gemcitabine hydrochloride, triapine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, Biphenotypic Leukemia
- Interventions
- Sorafenib, Cytarabine, Clofarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 31 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma
- Interventions
- educational intervention, informational intervention, internet-based intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration, psychosocial assessment and care, quality-of-life assessment, standard follow-up care
- Other · Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 2 Months to 18 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 6
- States / cities
- Duarte, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Interventions
- iC9-CAR19 cells, Rimiducid, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 3 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2037
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia
- Interventions
- Rituximab, Alemtuzumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 3 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia
- Interventions
- Roginolisib, Obinutuzumab, Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia, Obesity
- Interventions
- Tirzepatide, Resistance Exercise, Lifestyle Counseling
- Drug · Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
- Interventions
- CD19.CAR-multiVST for Group A, CD19.CAR-multiVST for Group B
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2040
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Acute Lymphocytic
- Interventions
- Copanlisib
- Drug
- Lead sponsor
- Dorothy Sipkins, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lymphoma
- Interventions
- Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX)
- Procedure · Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Interventions
- MLN4924, Azacitidine
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Stanford, California • Chicago, Illinois • Baltimore, Maryland + 3 more
- Conditions
- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Interventions
- lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 16
- States / cities
- La Jolla, California • Rancho Mirage, California • Stanford, California + 12 more
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- Interventions
- TGR-1202, Ibrutinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Monterey, California • Hartford, Connecticut • Brewer, Maine + 1 more
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
- Interventions
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
- Drug
- Lead sponsor
- David Wald
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Pneumococcal Polyvalent Vaccine
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio